Mergers & Acquisitions Mergers & Acquisitions

AbbVie clears first antitrust hurdle with US clearance of Immunogen, faces Cerevel deadline next week

By Flavia Fortes
  • 08 Feb 2024 20:23
  • 08 Feb 2024 21:05
AbbVie today gained US antitrust clearance for its proposed $10 billion acquisition of cancer biotech company Immunogen, the first of its two multi-billion acquisitions for complementary assets.
AbbVie said today that the waiting period under the Hart-Scott-Rodino Act expired Feb. 7 without action by the Federal Trade Commission (see here).

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers

Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News